Oncolytics reports updated results from study of pelareorep plus atezolizumab

Oncolytics (ONCY) Biotech announced updated results from the single-arm squamous cell anal carcinoma cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab in patients with greater than or equal to2L metastatic SCAC. Patients from this cohort continue to be followed, and additional efficacy data are expected to be reported. The combination of pelareorep and atezolizumab achieved an objective response rate of 30% (six among 20 evaluable patients). This represents a greater than 2x improvement over the historical benchmark of 13.8% ORR reported for the only FDA-approved immunotherapy for 2L SCAC. Importantly, there have been two durable complete responses among the six responders, with one ongoing beyond two years, and the other lasting 15 months. In addition, another patient has an ongoing response at 64 weeks. The overall median duration of response for patients receiving pelareorep and atezolizumab is 15.5 months compared to 9.5 months for the current standard of care at this stage of treatment. These updated results from this ongoing SCAC cohort reinforce the potential of pelareorep to drive durable immunologic tumor control in gastrointestinal tumors. The results also demonstrate the durability and depth of responses achievable with the combination of pelareorep and checkpoint inhibitors without chemotherapy.